New Ovarian Cancer Test Brings Hope to Thousands

Women fighting platinum-resistant ovarian cancer just gained a powerful new ally in their battle for survival.

Labcorp has launched nationwide access to a newly FDA-approved diagnostic test that identifies which ovarian cancer patients can benefit from KEYTRUDA, a groundbreaking immunotherapy treatment. The test, called PD-L1 IHC 22C3 pharmDx, became available in April 2026 and represents the first complete treatment pathway for patients with this challenging form of cancer.

The timing couldn't be more critical. About 80% of women with ovarian cancer see their disease return after initial treatment, and many develop resistance to platinum-based chemotherapy. For these patients, treatment options have been desperately limited, and survival rates remain heartbreakingly low.

KEYTRUDA and its companion formulation KEYTRUDA QLEX offer something these women haven't had before: real hope. Clinical trials showed the treatments significantly reduced disease progression and improved overall survival when combined with standard chemotherapy. The FDA approved both the test and treatments simultaneously in February 2026, recognizing the urgent need for better options.

"Platinum-resistant ovarian cancer is incurable, and current treatment options offer limited and short-lived benefits for patients," said Dr. Marcia Eisenberg, Chief Scientific Officer at Labcorp. She emphasized that rapid nationwide access to testing means eligible patients can quickly connect with potentially life-extending therapy.

Labcorp prepared for this moment by participating in early validation programs, ensuring their team was trained and ready the moment FDA approval came through. This preparation means women across the country can now get tested at Labcorp facilities without delays.

The Ripple Effect

This breakthrough extends beyond individual patients to transform how doctors approach one of oncology's toughest challenges. Clinicians now have a clear roadmap: test for PD-L1 expression, identify eligible patients, and offer treatments proven to work. The companion diagnostic model ensures the right patients receive the right treatment at the right time, maximizing benefit while minimizing unnecessary exposure to therapies that won't help.

The approval also signals growing momentum in precision medicine, where diagnostics and treatments work hand-in-hand. As more companion diagnostics become available, doctors gain better tools to personalize cancer care and give patients realistic hope based on their specific cancer's characteristics.

For the thousands of women facing platinum-resistant ovarian cancer, the message is clear: science hasn't given up on you, and neither should you.